A detailed history of Bailard, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Bailard, Inc. holds 12,700 shares of IOVA stock, worth $93,853. This represents 0.01% of its overall portfolio holdings.

Number of Shares
12,700
Previous 12,700 -0.0%
Holding current value
$93,853
Previous $103,000 82.52%
% of portfolio
0.01%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 02, 2024

BUY
$3.3 - $8.89 $41,910 - $112,903
12,700 New
12,700 $103,000
Q2 2021

Aug 13, 2021

SELL
$16.33 - $33.07 $191,060 - $386,919
-11,700 Closed
0 $0
Q4 2020

Feb 03, 2021

SELL
$28.04 - $50.26 $168,240 - $301,560
-6,000 Reduced 33.9%
11,700 $543,000
Q3 2020

Nov 10, 2020

SELL
$27.75 - $36.3 $19,425 - $25,409
-700 Reduced 3.8%
17,700 $583,000
Q2 2020

Aug 12, 2020

SELL
$27.21 - $41.0 $1.31 Million - $1.98 Million
-48,200 Reduced 72.37%
18,400 $505,000
Q1 2020

Apr 16, 2020

SELL
$19.54 - $38.85 $1.82 Million - $3.61 Million
-92,900 Reduced 58.24%
66,600 $1.99 Million
Q4 2019

Jan 31, 2020

SELL
$17.95 - $29.41 $231,555 - $379,389
-12,900 Reduced 7.48%
159,500 $4.42 Million
Q3 2019

Oct 18, 2019

BUY
$17.99 - $26.0 $3.1 Million - $4.48 Million
172,400 New
172,400 $3.14 Million

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.17B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Bailard, Inc. Portfolio

Follow Bailard, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.